ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues...
Transcript of ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues...
![Page 1: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/1.jpg)
ESAs and Outcomes in CKD Patients
Philip Lui PharmDThe 13th Annual Contemporary Therapeutic
Issues in Cardiovascular DiseaseMay 8, 2010
![Page 2: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/2.jpg)
Anemia in CKD Patients
• Associated with impairment in quality of life, reduced energy, neurocognitive decline, decreased exercise capacity, and increased mortality
• Erythropoiesis-stimulating agents (ESAs): epoetin alfa, epoetin beta, darbepoetin alfa
![Page 3: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/3.jpg)
Hemoglobin Targets
Significantly higher primary end point of death, MI, hospitalization for CHF, or stroke in higher hemoglobin target group
No significant difference
NEJM 2006;355:2071-84, NEJM 2006;355:2085-98
![Page 4: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/4.jpg)
Normal Hematocrit study
NEJM 1998;339:584-90
![Page 5: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/5.jpg)
NEJM 2009;361:2019-32
![Page 6: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/6.jpg)
TREAT
• Randomized, double-blind, placebo-controlled trial
• 4038 patients with type 2 diabetes, chronic kidney disease not on dialysis and anemia
• Darbepoetin to increase Hb to 130g/L versus placebo with rescue darbepoetin if Hb < 90g/L
![Page 7: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/7.jpg)
TREAT
NEJM 2009;361:2019-32
![Page 8: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/8.jpg)
TREATDarbepoetin (n=2012)
N (%)Placebo (n=2026)
N (%)P value
CV composite 632 (31.4) 602 (29.7) 0.41
Death from any cause 412 (20.5) 395 (19.5) 0.48
Myocardial infarction 124 (6.2) 129 (6.4) 0.73
Stroke 101 (5.0) 53 (2.6) <0.001
Heart failure 205 (10.2) 229 (11.3) 0.24
Myocardial ischemia 41 (2.0) 49 (2.4) 0.40
Renal composite 652 (32.4) 618 (30.5) 0.29
![Page 9: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/9.jpg)
TREAT
Darbepoetin group• More thromboembolism (2.0% vs. 1.1%)• More deaths from cancer among patients with
history of cancer (7.4% vs. 0.6%)• Fewer transfusions (14.8% vs. 24.5%)• Quality of life scores
![Page 10: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/10.jpg)
Implications
• Placebo controlled• Largest trial with the most adjudicated events• Did not confirm the higher rates of death and
hospitalization for CHF in CHOIR• Darbepoetin confers no benefit in mortality or
cardiovascular or renal outcomes compared to placebo
![Page 11: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/11.jpg)
Stroke Risks
CHOIR, CREATE• No difference
Normal Hematocrit study• High Hct 6.3% vs. low Hct 4.7% (p=ns)
Canadian-European Normalization of Hemoglobin with Erythropoietin trial• High Hb 4% vs. low Hb 1% (p<0.05)
NEJM 1998;339:584-90, J Am Soc Neph 2005;16:2180-9
![Page 12: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/12.jpg)
Potential Mechanisms
• Increased viscosity and wall shear stress• Thrombocytosis• Increased platelet reactivity, adhesion, and
aggregation• Increased arterial pressure
Am J Kidney Dis 2009;53(5):733-6, Adv Chronic Kidney Dis 2009;16(2):131-42
![Page 13: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/13.jpg)
TREAT Quality of Life
• FACT–Fatigue • Improvement in mean score - darbepoetin 4.2 vs.
placebo 2.8• Clinically meaningful change of 3 points -
darbepoetin 55% vs. placebo 50%• SF-36
• No significant difference
![Page 14: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/14.jpg)
Quality of Life
CHOIR (LASA, KDQ, SF-36)• Both groups improved, no significant difference
CREATE (SF-36)• Significant improvements in high Hb target group
![Page 15: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/15.jpg)
Outstanding Unknowns
• Dose• Hemoglobin target• ESA hyporesponsiveness• Different dosing strategy• Class effect• Patient population• Quality of Life
![Page 16: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/16.jpg)
Treatment of Anemia
CKD patients not on dialysis• Minimize ESA use for mild to moderate anemia
(90-110g/L) especially for those with minimal fatigue
• Minimize ESA use for those with history of cancer or stroke
• Transplant candidates or those with severe anemia (<90g/L) may consider long term ESA to maintain Hb between 90g/L and 110g/L
J Am Soc Neph 2010;21:1-13
![Page 17: ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.](https://reader036.fdocuments.us/reader036/viewer/2022062713/56649ccd5503460f94997f80/html5/thumbnails/17.jpg)
Treatment of Anemia
Dialysis patients• Use lowest dose to maintain Hb above 90g/L• Pursue other strategies to lower ESA dose (eg. SC
instead of IV, peritoneal dialysis, iron, treat inflammation)
• Minimize ESA use in patients who are within 2 years of diagnosis of malignancy
J Am Soc Neph 2010;21:543-55